| Corporate-sponsored trial |
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer |
Department of Breast Surgery |
| Corporate-sponsored trial |
An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults with Advanced Solid Tumors |
Department of Gynecology and Obstetrics |
| Corporate-sponsored trial |
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies (TITAN) |
Department of Rheumatology and Clinical Immunology |
| Corporate-sponsored trial |
AcTFirst: A phase III, open-label, multi-center, randomized study comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration resistant prostate cancer. (CAAA817B12301) |
Department of Radiation Oncology and Image-Applied Therapy |
| Corporate-sponsored trial |
Efficacy and safety of teplizumab in the treatment of Japanese pediatric and adult participants aged 8 to 34 years with Stage 2 type 1 diabetes: A multicenter, randomized, open-label, controlled study. |
Department of Diabetes, Endocrinology and Nutrition |
| Corporate-sponsored trial |
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT, MK-2870) as a Monotherapy and in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less than 10 (TroFuse-011) |
Department of Breast Surgery |
| Corporate-sponsored trial |
A Phase 2 Study of Necitumumab in Patients with Unresectable, Advanced or Recurrent Esophageal Cancer or Gastric Cancer with EGFR Amplification (NEO-GEAR Study) |
Department of Medical Oncology |
| Corporate-sponsored trial |
Open-label study comparing AAA817 versus standard of care in the treatment of previously treated PSMA-positive mCRPC adults who progressed on or after [177Lu]Lu-PSMA targeted therapy. (CAAA817A12201) |
Department of Radiation Oncology and Image-Applied Therapy |
| Corporate-sponsored trial |
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (J5Q-OX-JRDA) |
Department of Early Clinical Development |
| Corporate-sponsored trial |
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer |
Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery |
| Corporate-sponsored trial |
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations |
Department of Respiratory Medicine |
| Corporate-sponsored trial |
A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma (S095032 (AG-881)) |
Department of Neurosurgery |
| Corporate-sponsored trial |
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
Department of Respiratory Medicine |
| Corporate-sponsored trial |
A Study to Learn About Study Medicine ALTA2618 in Adults with AKT1 E17K-Mutant Solid Tumors |
Department of Early Clinical Development |
| Corporate-sponsored trial |
A phase 3, Randomized, Double-Blind, Placebo-Controlled Study of NovoTTF-100A System (TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus NovoTTF-100A System Concomitant with Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE-D58) |
Department of Neurosurgery |
| Investigator-initiated trial |
A basket trial of DS-8201a, a novel HER2-targeted antibody-drug conjugate, for HER2 amplified solid tumors identified by ctDNA analysis (HERALD trial) |
Department of Medical Oncology |
| Corporate-sponsored trial |
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants with Locally Advanced or Metastatic Cholangiocarcinoma with an IDH1 Mutation (S095031-210) |
Department of Early Clinical Development |
| Corporate-sponsored trial |
A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292) |
Department of Breast Surgery |
| Corporate-sponsored trial |
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician’s Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2 positive Breast Cancer |
Department of Breast Surgery |
| Corporate-sponsored trial |
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer |
Department of Medical Oncology |
| Corporate-sponsored trial |
Beamion BCGC-1: A Phase Ib and Phase II trial of zongertinib in combination with intravenous trastuzumab deruxtecan (T-DXd) or in combination with intravenous trastuzumab emtansine (T-DM1) for treatment of patients with advanced HER2+ mBC and mGEAC (1479-0012/ Beamion BCGC-1) |
Department of Breast Surgery |
| Corporate-sponsored trial |
An open-label study to assess safety,efficacy,and cellular kinetics of YTB323 in treatment resistant generalized myasthenia gravis (CYTB323O12101) |
Department of Neurology |
| Corporate-sponsored trial |
An Open-Label Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Participants with Previously Untreated FLIPI 2-5 Follicular Lymphoma |
Department of Hematology |
| Corporate-sponsored trial |
MK-2870 with or without pembrolizumab in HR+/HER2- metastatic breast cancer |
Department of Breast Surgery |
| Corporate-sponsored trial |
MK-2870 Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR |
Department of Breast Surgery |
| Corporate-sponsored trial |
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia |
Department of Hematology |
| Corporate-sponsored trial |
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (The ACTION Study) |
Department of Neurosurgery |
| Corporate-sponsored trial |
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION-Breast04) |
Department of Breast Surgery |
| Corporate-sponsored trial |
A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN) (CYTB323J12201) |
Department of Rheumatology and Clinical Immunology |
| Corporate-sponsored trial |
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01) (EvoPAR-Breast01) |
Department of Breast Surgery |
| Corporate-sponsored trial |
[M24-742]First-in-Human Study of ABBV-969 in Metastatic Castration-Resistant Prostate Cancer |
Department of Early Clinical Development |
| Corporate-sponsored trial |
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors (J5A-OX-JZWA) |
Department of Early Clinical Development |
| Corporate-sponsored trial |
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (AZUR-2) |
Department of Medical Oncology |
| Corporate-sponsored trial |
PSMA-DC: An Open-label study comparing lutetium (177Lu) vipivotide tetraxetan (also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617) versus observation in PSMA positive OMPC（CAAA617D12302）. |
Department of Radiation Oncology and Image-Applied Therapy |
| Corporate-sponsored trial |
Phase I Study of AK1910 in Healthy Japanese Subjects, Healthy Caucasian Subjects, Patients with Systemic Lupus Erythematosus (Single Dose and Multiple Dose Study) |
Department of Rheumatology and Clinical Immunology |
| Corporate-sponsored trial |
First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants with B-cell Malignancies |
Department of Hematology |
| Corporate-sponsored trial |
[M23-385]A Phase 1 study of ABBV-706 alone or in combination in adult subjects with advanced solid tumors. |
Department of Early Clinical Development |
| Corporate-sponsored trial |
[M24-311]Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous（IV）ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab |
Department of Early Clinical Development |
| Corporate-sponsored trial |
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) |
Department of Respiratory Medicine |
| Corporate-sponsored trial |
AB122 Platform study |
Department of Medical Oncology |
| Investigator-initiated trial |
PRIME Study (PRIME Study) |
Department of Nephrology |
| Investigator-initiated trial |
NCCH2101/MK011 trial (Perfume trial) |
Department of Medical Oncology |
| Investigator-initiated trial |
Phase II Trial to Evaluate the Efficacy and Safety of Combination Therapy with Immune Checkpoint Inhibitors and Photodynamic Therapy |
Department of Medical Oncology |
| Corporate-sponsored trial |
EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING IDECABTAGENE VICLEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE (BB2121-EAP-001) |
Department of Hematology |
| Corporate-sponsored trial |
A Japanese Phase 2 study of 177Lu-PSMA-617 in participants with PSMA(+) mCRPC (CAAA617A11201) |
Department of Radiation Oncology and Image-Applied Therapy |
| Corporate-sponsored trial |
Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release (JCAR017-EAP-001) |
Department of Hematology |
| Investigator-initiated trial |
Clinical Trial of Alectinib in Patients with ALK positive rare cancer |
Department of Medical Oncology |
